Paul Tudor Jones sees potential market rally after late October
Daniel Barber, President and CEO of Aquestive Therapeutics Inc (NASDAQ:AQST), sold 91,343 shares of common stock on September 26, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales were executed at a weighted average price of $6.0343, resulting in a total transaction value of $551191. The transaction comes as the company’s stock has shown remarkable strength, with InvestingPro data showing a 98% return over the past six months and the stock trading near its 52-week high of $6.43.
The prices for the sales ranged from $6.00 to $6.11 per share. Following the transaction, Barber directly owns 923430 shares of Aquestive Therapeutics . With a market capitalization of approximately $694 million and strong analyst support (consensus recommendation of 1.4 out of 5, where 1 is a Strong Buy), the company continues to draw investor attention. Discover more valuable insights about AQST with a comprehensive InvestingPro subscription, including 12 additional ProTips and detailed financial analysis.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan.
In other recent news, Aquestive Therapeutics announced that the U.S. Food and Drug Administration will not require an advisory committee meeting for its Anaphylm sublingual film, keeping the company on track for a regulatory decision by January 31, 2026. Aquestive also secured a $75 million funding deal with RTW Investments, contingent upon FDA approval of Anaphylm, which is intended to aid in its commercialization through 2027. The company further strengthened its financial position by pricing an $85 million public offering of 21,250,000 shares at $4.00 per share, with the transaction expected to close on or about August 15, 2025.
In terms of market analysis, Piper Sandler reiterated its Overweight rating and $5.00 price target on Aquestive, citing positive feedback from allergists about Anaphylm’s non-injectable convenience and dosing profile. Similarly, Cantor Fitzgerald maintained its Overweight rating with a $15.00 price target, highlighting the potential market shift toward needle-less epinephrine delivery systems. Both firms expressed confidence in Aquestive’s prospects in the epinephrine delivery market. These developments underscore significant interest and investment in Aquestive’s innovative approach to severe allergic reactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.